Academic Journal
أعرض في EDS

HLA-DPB1 *05:01 and HLA-A *11:01 Is Associated with Adverse Drug Reactions to Isoniazid and Rifampin for Treatment of Latent Tuberculosis Infection in South Korea

التفاصيل البيبلوغرافية
العنوان: HLA-DPB1 *05:01 and HLA-A *11:01 Is Associated with Adverse Drug Reactions to Isoniazid and Rifampin for Treatment of Latent Tuberculosis Infection in South Korea
المؤلفون: Bomi Kim, Jungok Kim, Sun-Young Yoon, Hae Suk Cheong, Min-Jung Kwon, Joon-Sup Yeom, Han-Na Kim, Eun-Jeong Joo
المصدر: Journal of Clinical Medicine, Vol 13, Iss 12, p 3563 (2024)
بيانات النشر: MDPI AG
سنة النشر: 2024
المجموعة: Directory of Open Access Journals: DOAJ Articles
مصطلحات موضوعية: adverse drug reactions, drug hypersensitivity, HLA-A *11:01 antigen, HLA-DPB1 *05:01 antigen, latent tuberculosis, Medicine
الوصف: Background: Screening and treating healthcare workers (HCWs) for latent tuberculosis infection (LTBI) are essential for tuberculosis (TB) infection control. Adverse drug reactions (ADRs) to anti-TB drugs present challenges to patient safety and treatment completion. Objective: This study investigated the association between human leukocyte antigen (HLA) alleles and the risk of ADRs, especially drug hypersensitivity (DHS) and hepatotoxicity, in HCWs with LTBI receiving isoniazid (INH) and rifampin (RIF) therapy. Methods: Korean HCWs with LTBI who received a 3 month INH and RIF regimen were included in this study. HLA genotyping was performed on HCWs who experienced ADRs during treatment, as well as the control group consisted of individuals who did not develop ADRs. Results: Of the 67 patients, 29 (43.2%) experienced ADRs during INH and RIF therapy. The HLA-A *11:01 allele was more frequent in patients with DHS without hepatotoxicity (DSH+/H−) compared to the control group (DHS−/H−) (4/9, 44.4% vs. 3/38, 7.9%; odd ratio [OR], 8.554; 95% confidence interval [CI], 1.415–59.869; p = 0.018). Conversely, HLA-DPB1 *05:01 was associated with an increased risk of hepatotoxicity regardless of DHS (10/20, 50% vs. 5/38, 13.2%; OR, 5.323; 95% CI, 1.493–21.518; p = 0.011). In the DHS with hepatotoxicity group (DHS+/H+), HLA-DPB1 *05:01 was present in a higher proportion (3/5, 60% vs. 5/38, 13.2%; OR, 8.912; 95% CI, 1.110–92.993; p = 0.037), whereas HLA-A *11:01 was not observed in this group. Conclusions: The HLA-A *11:01 allele was associated with an increased risk of DHS without hepatotoxicity, whereas the HLA-DPB1 *05:01 allele was associated with an increased risk of hepatotoxicity.
نوع الوثيقة: article in journal/newspaper
اللغة: English
تدمد: 2077-0383
Relation: https://www.mdpi.com/2077-0383/13/12/3563; https://doaj.org/toc/2077-0383; https://doaj.org/article/bd494c29a3de4a31a3b5129095e7e4d9
DOI: 10.3390/jcm13123563
الاتاحة: https://doi.org/10.3390/jcm13123563
https://doaj.org/article/bd494c29a3de4a31a3b5129095e7e4d9
رقم الانضمام: edsbas.20047BB2
قاعدة البيانات: BASE
الوصف
تدمد:20770383
DOI:10.3390/jcm13123563